Eli Lilly Said Prices Would Fall First. Now Volume Has to Prove the Bet.

On January 30, five days before Eli Lilly reported its fourth-quarter results, David Ricks told CNBC what the numbers were about to show. Prices would step down early in the year. The volume that would make up for it would ramp in the back half.

It was a specific claim about timing, not just growth. For a company selling medicines in a market expanding at extraordinary speed, the distinction matters. Lower prices can widen access, but they also reduce what a manufacturer earns per prescription. The bet works only if enough additional treatment starts offset that pressure.

Lilly’s results through June show the tension clearly. Revenue grew between 43% and 56% year over year in each of the three reported quarters spanning the end of 2025 and the first half of 2026. Volume grew faster than revenue, while the average price Lilly realized across its products and markets fell. That establishes the price pressure and shows that demand has so far more than offset it. It does not, by itself, prove that the government agreement caused either trend.

There is now an early signal from the Medicare GLP-1 Bridge program. In a September interview with CNBC, Ricks said about 700,000 seniors had started GLP-1 treatment since the program began in July, and that Lilly medicines accounted for roughly 70% of those new starts. Those figures are management’s account of early uptake, not a substitute for quarterly financial disclosure. The next question is whether that demand becomes durable volume and revenue at the prices Lilly has agreed to accept.

Lilly is due to report third-quarter results on October 29. The numbers should offer the first quarterly view of a period that includes the Medicare GLP-1 Bridge program.

What Lilly agreed to

Lilly announced the agreement with the US government on November 6, 2025, and its own description of the terms is specific enough to be worth reading closely.

Medicare beneficiaries would pay no more than $50 a month for Zepbound in its multi-dose pen, and for the obesity pill orforglipron once approved, starting as early as April 1, 2026. States could extend access through Medicaid. For patients paying cash through LillyDirect, the lowest dose of Zepbound would cost $299 a month and higher doses up to $449, which Lilly described as $50 below the direct-to-patient prices then in place. Orforglipron would start at $149 and run to $399 depending on dose. Emgality, Trulicity and Mounjaro would be added to LillyDirect at 50% to 60% below list price. Pricing obligations in the commercial insurance channel were outside the scope of the agreement.

In return, Lilly said it would receive three years of tariff relief and would not be subject to future pricing mandates. The release also cited more than $50 billion in US manufacturing investment.

Two details change how the numbers read later. The first is timing. April 1 was only the earliest possible start. Medicare’s weight-loss coverage began on July 1, 2026, as the Medicare GLP-1 Bridge, with a $50 monthly beneficiary copay for eligible patients and prior authorization requirements. The program is scheduled to run through December 31, 2027. It could not have contributed to Lilly’s first-half sales, although other price changes and other sources of demand were already affecting the results.

A second distinction matters just as much: the amount a patient pays is not the same as the amount a manufacturer realizes. The administration announced a $245 monthly program price, but that figure should not be treated casually as Lilly’s per-patient revenue. CMS payment and pharmacy-reimbursement mechanics are more specific, while Lilly’s reported realized price is a blended figure shaped by rebates, discounts, product mix and geography.

The price drop was guided before it happened

Around the fourth-quarter report in February, a Lilly executive told investors that price would be a drag on 2026 growth in the low to mid-teens, in percentage terms. Ricks had already said the volume that would make up for it would come in the back half of the year.

That gives the first-half price decline some context. Worldwide realized price fell 13% in the first quarter and 13% again in the second, in line with the range management described in February. The decline was forecast, so it should not be read as a sign that something went wrong. It is also not, by itself, evidence that the bet is working. It shows that realized-price pressure was already visible.

What the latest quarters show

The fourth quarter of 2025 is the baseline. Revenue was $19.29 billion, up 43%. Volume grew 46% and worldwide realized price fell 5%. In the United States, volume rose 50% and price fell 7%.

The first quarter of 2026 is where the price step appears. Revenue rose 56% to $19.80 billion on 65% more volume, and worldwide realized price fell 13%. Lilly attributed the US decline mainly to Zepbound and Taltz and pointed to its earlier cuts to Zepbound cash prices, with a favorable one-time rebate and discount adjustment cushioning the effect on Mounjaro and Zepbound. Outside the United States, revenue grew 81% on 95% more volume while price fell 25%, which the company tied primarily to Mounjaro's addition to China's National Reimbursement Drug List. The release mentions the government agreement only in its forward-looking statements. It does not link the agreement to the first-quarter price change.

One detail in that quarter is easy to miss. US revenue was $12.1 billion, below the $12.9 billion reported in the fourth quarter, while revenue outside the United States reached $7.7 billion.

The second quarter brought the first large sequential step. Revenue was $22.97 billion, up 48% from a year earlier and about 16% above the first quarter. Volume rose 60% and worldwide price fell 13% again. US revenue climbed to $14.4 billion, up 33% on 37% more volume, with realized price down only 3%. That figure flatters the trend. Lilly's release says adjustments to rebate and discount estimates, mainly on Trulicity, Zepbound and Mounjaro, offset part of the decline, and that without them US price would have fallen by about 9%. Outside the United States, revenue was $8.6 billion, up 80%, on volume growth of 113% and a price decline of 36%, again attributed mostly to the China listing.

Read in order, the quarters support the first half of what Ricks described. The price step arrived in the first quarter and held in the second. Worldwide realized price moved from down 5% to down 13% to down 13%, and the underlying US figure moved from down 7% to down 7% to roughly down 9%. Volume outran price in every one of those quarters, and revenue growth stayed above 40% throughout.

The second half of the sequence is harder to read in these numbers. Year-over-year volume growth was 46%, 65% and 60% across the three quarters, which is strong but not rising. In the United States it slowed from 50% to 49% to 37%. The acceleration is outside the country, where volume growth went from 95% to 113%, and that is the market where the price decline is steepest. Some slowing is expected as each quarter is measured against a larger year-earlier base, and Lilly has not said how much of it is that. But the volume that Ricks tied to the second half has to come from somewhere, and the part of the business that most needs to speed up in the United States is the one that has slowed most.

Four prices, none of them the one in the results

For a Zepbound patient, several prices can coexist. The list price is the published price before negotiated discounts. The patient price is what someone pays at the pharmacy: a $50 copay for eligible Medicare Bridge participants, a commercial-plan copay, or the cash price offered through LillyDirect. The government-announced program price is a separate figure, and the actual payment path includes program and pharmacy rules. The realized price in Lilly’s earnings is different again: a blended measure after discounts, rebates and the mix of products and markets.

Each one moves for a different reason. A cut to the cash price changes what one group of patients pays and leaves what insurers pay untouched. A new public program may lower a patient’s out-of-pocket cost while adding prescriptions from people who were previously untreated. A change in the estimate for rebates, like the one Lilly booked in the second quarter, moves realized price without any change to a price list. A worldwide figure also shifts with where the volume is sold.

That is why a 13% fall in worldwide realized price should not be described as a 13% price cut for all patients. It is also why the entire decline cannot be assigned to the government deal. Lilly’s disclosures identify other drivers, including the China reimbursement listing and rebate adjustments.

What the guidance implies for the second half

Lilly has raised its revenue forecast at every report this year. It started 2026 at $80 billion to $83 billion, moved to $82 billion to $85 billion on April 30, and on August 5 raised it to $85 billion to $87 billion.

The arithmetic behind the latest range is worth doing, because it says something the headline does not. Revenue for the first half was $42.77 billion, the sum of $19.80 billion and $22.97 billion. A full-year figure of $85 billion to $87 billion therefore leaves $42.2 billion to $44.2 billion for the second half. Spread over two quarters, that is $21.1 billion to $22.1 billion each, below the $22.97 billion Lilly reported in the second quarter. Against the second half of 2025, which totaled $36.89 billion across the third and fourth quarters, the range implies growth of roughly 14% to 20%. Every quarter since the fourth of 2025 has grown between 43% and 56%.

There are two reasonable readings. Lilly has raised its forecast three times, which suggests the business has continued to outperform the company’s earlier expectations. At the same time, the latest range builds in a slower growth rate for the second half than the recent quarterly results. But guidance is not a transparent map of management’s assumptions. It may already include expectations for stronger volume, lower prices, product launches, currency effects and other moving parts. The range alone cannot prove that management has excluded the volume ramp Ricks described, nor that any ramp must show up only as revenue above guidance. The next release will help show whether the moderation reflects prudent forecasting, a tougher comparison, changing price mix, or evidence that the volume-and-price balance is becoming harder to maintain.

Concentration and the generic question

The volume bet is a bet on two products. Mounjaro and Zepbound together produced $14.8 billion of the $22.97 billion in second-quarter revenue, close to two-thirds of the total by simple division. In the first quarter the figure was about 65%. Lilly does not report a concentration percentage, but its filings list dependence on a small number of products among its risk factors, and the numbers above show why.

That concentration is what gives the generic question its weight. In its second-quarter filing, Lilly disclosed that it had received notice that multiple generic-drug manufacturers had filed applications involving Mounjaro and Zepbound before certain patents expired. Lilly said it intended to defend its intellectual property. An application is not an approval, and it does not mean a generic product is about to enter the US market. The patent and litigation process remains a separate issue from the current volume trend.

For the article's central question, the practical meaning is narrow. Nothing in the current numbers is affected by a generic competitor. But a company that has agreed to lower prices in exchange for volume is making a multi-year commitment, and the volume it builds has to be defended for a long time against the competitor that will eventually come.

The case against, and the case for

The agreement has critics, and their objections are mostly about information and about who ends up paying. On November 18, 2025, Senator Ruben Gallego wrote to Ricks and to Novo Nordisk chief executive Mike Doustdar. He said he supported wider Medicare coverage of obesity drugs but objected that so little of the deal was public, and he noted the three-year tariff exemption Lilly reportedly received. His letter asked how the administration arrived at the $245 Medicare price, which countries and benchmarks set the pricing, and whether costs would move onto private insurers, employers or Medicare. He also argued that a cash-pay model could raise costs for insured patients who already pay lower copays.

Those objections matter because they point at what the quarterly results cannot show. The numbers tell a reader how much Lilly sold and at what blended price. They do not say whether the cash and Medicare channels are reaching people who would otherwise have gone without, or people whose treatment would have been covered anyway.

There is also a case for the agreement. Lower out-of-pocket costs can make treatment possible for people who could not previously afford it, and the early Medicare uptake figures Ricks reported suggest the program is attracting patients. But those figures are a company executive’s reported snapshot, not a full independent accounting of program outcomes. They also do not tell readers how much incremental revenue those prescriptions will generate or what Lilly’s net realization will be. The financial evidence is mixed in a useful way: revenue growth remained strong while realized prices declined, but the growth figures cannot be credited to the agreement alone.

What the third quarter has to show

Lilly reports on October 29. It will be the first quarter to include the Medicare GLP-1 Bridge, which began on July 1, and so the first that can test the second half of the sequence Ricks described. Four numbers will say more than the revenue headline.

The first is US volume growth. It was 37% in the second quarter, down from 49% in the first. A rebound would be consistent with strengthening demand, though it would not by itself prove that the Bridge caused it. Another slowdown would make it harder to argue that the US market is accelerating as expected.

The second is US realized price. The reported decline in the second quarter was 3%, but about 9% without the rebate and discount adjustments. How large those adjustments are in the third quarter will show how much of the price story is being cushioned by estimates.

The third is revenue against guidance. The current full-year range implies second-half revenue of about $42.2 billion–$44.2 billion. A third-quarter result near the second quarter’s $22.97 billion would indicate that the company is running above the average quarterly pace implied by its guidance; a lower result would need to be read alongside the fourth-quarter outlook and any change in the full-year range.

The fourth is the guidance itself, and whether Lilly raises it a fourth time.

The verdict, so far

The first half supports one part of Ricks’s forecast: lower realized prices arrived alongside strong volume growth, and revenue continued to rise sharply. It does not prove that the government agreement caused the growth, and it does not yet settle whether the second-half volume ramp will be large enough to sustain the economics of the strategy.

There is a promising early access signal. Ricks reported in September that about 700,000 seniors had started GLP-1 treatment through the Medicare expansion and that roughly 70% were using Lilly medicines. But uptake figures are not the same as quarterly revenue, and the reported worldwide price decline reflects more than one policy or product.

The next test is not whether Lilly can sell more medicine at lower prices in a market that is already growing quickly. It is whether new access creates enough additional, sustained demand to make the lower-price model work—without relying on rebate adjustments to soften the reported decline, and without leaving the business excessively dependent on two products. That answer is not yet in the numbers. The October 29 report should move the question forward.